Possible long term breakout in the stock which has made a nice recovery on the back of surprise.
It's possible it may consolidate for a few days on the market weakness.
Average analysts price target $13 | BUY rating
High 14% short interest
Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
1) Sign Up for our Free Email Newsletter @
2) Sign Up for our Free Text Message Notifications
by Texting 'GAINS' to 67076.
(*It's FREE, however Msg&Data rates may apply